Filing Details

Accession Number:
0001418812-14-000081
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-11-26 16:11:41
Reporting Period:
2014-11-24
Filing Date:
2014-11-26
Accepted Time:
2014-11-26 16:11:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885590 Valeant Pharmaceuticals International Inc. VRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1159187 W Jeffrey Ubben One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1351069 Valueact Capital Management, L.p. One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1351073 Valueact Capital Management, Llc One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1418812 Va Partners I, Llc One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1418813 Valueact Holdings Gp, Llc One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1418814 Valueact Holdings, L.p. One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1464912 Valueact Capital Master Fund, L.p. One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
1579734 Valueact Co-Invest Master Fund, L.p. One Letterman Drive
Building D, 4Th Floor
San Francisco CA 94129
Yes No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, No Par Value Acquisiton 2014-11-24 210,000 $142.25 17,780,936 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, No Par Value 1,352,941 Indirect See footnotes
Footnotes
  1. Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  2. The securities reported herein are directly beneficially owned by ValueAct Capital Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P. , (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P. , (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P. Jeffrey W. Ubben is a member of the management board of ValueAct Holdings GP, LLC.
  3. The securities reported herein are directly beneficially owned by ValueAct Co-Invest Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) VA Partners I, LLC as General Partner of ValueAct Co-Invest Master Fund, L.P. , (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Co-Invest Master Fund, L.P. , (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P. Jeffrey W. Ubben is a member of the management board of ValueAct Holdings GP, LLC.